The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000619347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
4/05/2026
Date registered
Help: Date registered
20/05/2026
Date last updated
Help: Date last updated
20/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Screening for primary aldosteronism in postpartum women who have chronic hypertension
Scientific title
Screening for primary aldosteronism (PA) after hypertensive pregnancy: determining prevalence of PA in women who have pre-existing or new chronic hypertension after a hypertensive pregnancy
Additional trial identifiers [1] 317185 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hypertensive disorders of pregnancy 341764 0
Primary aldosteronism 341765 0
Condition category
Condition code
Cardiovascular 337841 337841 0 0
Hypertension
Reproductive Health and Childbirth 337842 337842 0 0
Childbirth and postnatal care
Metabolic and Endocrine 337960 337960 0 0
Other endocrine disorders

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
Women who had hypertension will be followed up postpartum. PA screening is now recommended for all adults with hypertension.
For those with pre-existing chronic hypertension, screening for PA will be performed at 6 weeks postpartum. For those with de novo hypertension, an assessment will be completed at 3 months postpartum to assess whether hypertension has resolved or continued (now meeting criteria for chronic hypertension). If new chronic hypertension is diagnosed then PA screening will be performed. If screening tests are positive, participants will proceed to confirmatory testing with their local endocrine department.
Intervention code [1] 333953 0
Diagnosis / Prognosis
Intervention code [2] 334044 0
Diagnosis / Prognosis
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345298 0
Diagnosis of PA
Timepoint [1] 345298 0
PA screening will be performed at 6 weeks or 3 months postpartum, depending on participant category.
Secondary outcome [1] 461193 0
Rate of conversion from de novo hypertension in pregnancy to chronic hypertension
Timepoint [1] 461193 0
At 3 months postpartum
Secondary outcome [2] 461194 0
Rate of false negative (ARR <70) in participants on interfering medications such as the most commonly used antihypertensives postpartum, ACEi and calcium channel blockers (known to cause false negative by increasing renin)
Timepoint [2] 461194 0
At 6 weeks or 3 months postpartum, depending on participant category

Eligibility
Key inclusion criteria
Diagnosis of chronic hypertension, gestational hypertension, postpartum hypertension or preeclampsia
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Known diagnosis of primary aldosteronism

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321764 0
University
Name [1] 321764 0
Eastern Health Clinical School, Monash University
Country [1] 321764 0
Australia
Primary sponsor type
Hospital
Name
Eastern Health Clinical School
Address
Country
Australia
Secondary sponsor category [1] 324606 0
None
Name [1] 324606 0
Address [1] 324606 0
Country [1] 324606 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320311 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320311 0
Ethics committee country [1] 320311 0
Australia
Date submitted for ethics approval [1] 320311 0
15/05/2026
Approval date [1] 320311 0
Ethics approval number [1] 320311 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150046 0
Dr Madeleine Cosgrave
Address 150046 0
Department of Renal and Obstetric Medicine, Eastern Health. Level 2, 5 Arnold St, Box Hill VIC 3128
Country 150046 0
Australia
Phone 150046 0
+61 03 9091 8872
Fax 150046 0
Email 150046 0
Contact person for public queries
Name 150047 0
Madeleine Cosgrave
Address 150047 0
Department of Renal and Obstetric Medicine, Eastern Health. Level 2, 5 Arnold St, Box Hill VIC 3128
Country 150047 0
Australia
Phone 150047 0
+61 03 9091 8872
Fax 150047 0
Email 150047 0
Contact person for scientific queries
Name 150048 0
Madeleine Cosgrave
Address 150048 0
Department of Renal and Obstetric Medicine, Eastern Health. Level 2, 5 Arnold St, Box Hill VIC 3128
Country 150048 0
Australia
Phone 150048 0
+61 03 9091 8872
Fax 150048 0
Email 150048 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.